

The impact of genetic engineering on human health: Promises and risks.

Andrew Henslee*

Department of Chemical and Biomolecular Engineering, Ohio State University, USA

Introduction

Genetic engineering, a groundbreaking field of biotechnology, has revolutionized the way we approach human health. With the ability to manipulate DNA, scientists now have the power to prevent genetic disorders, treat diseases, and enhance human capabilities. However, as with any powerful technology, genetic engineering comes with both immense promises and significant risks. This article will explore the major advances in genetic engineering, its potential benefits for human health, and the ethical and safety concerns associated with its use [1].

One of the most promising applications of genetic engineering is gene therapy, which involves replacing, altering, or supplementing defective genes to treat or prevent genetic diseases. Disorders such as cystic fibrosis, hemophilia, and sickle cell anemia, which are caused by mutations in a single gene, are prime targets for gene therapy. The success of early clinical trials in correcting these genetic errors offers hope to millions of people who suffer from incurable hereditary conditions [2].

CRISPR-Cas9, a revolutionary gene-editing tool, has taken genetic engineering to new heights by allowing scientists to cut out and replace faulty DNA sequences with unprecedented accuracy. This technology has the potential to cure a wide range of diseases, including cancer, Alzheimer's, and HIV. Researchers are also exploring its application in creating genetically modified immune cells that can more effectively fight diseases like leukemia. CRISPR is ushering in an era of precision medicine where treatments can be tailored to a patient's genetic makeup [3].

Another significant promise of genetic engineering lies in germline editing, where modifications to the genes of embryos or reproductive cells can prevent the transmission of genetic disorders to future generations. This could potentially eradicate certain inherited diseases from the human population. Although still in the experimental stages, the ability to correct faulty genes before birth holds immense promise for reducing the global burden of genetic diseases [4].

Genetic engineering is also advancing the field of pharmacogenomics, which studies how an individual's genetic makeup influences their response to drugs. By understanding these genetic variations, doctors can prescribe medications that are more effective and have fewer side effects for each patient. This personalized approach to medicine could dramatically improve the success of treatments for a wide

range of conditions, from cardiovascular diseases to mental health disorders [5].

Despite its vast potential, genetic engineering poses several risks, particularly in its early stages. One of the primary concerns is the possibility of unintended genetic changes. CRISPR-Cas9, while highly precise, can occasionally cause off-target mutations, leading to unintended consequences in the genome. These unforeseen alterations could disrupt normal biological functions and potentially cause new diseases, some of which may not be immediately apparent [6].

Germline editing, while offering the potential to eradicate genetic diseases, raises significant ethical concerns. Any changes made to the germline are heritable, meaning they will be passed on to future generations. This opens the door to controversial applications such as "designer babies," where parents could potentially select for desirable traits like intelligence, physical appearance, or athletic ability. The ethical implications of allowing human genetic modification for non-therapeutic purposes have sparked a global debate on where the line should be drawn [7].

Another concern is that access to genetic therapies may exacerbate existing health disparities. Advanced genetic treatments, particularly those involving gene editing, are likely to be expensive, at least initially. This could limit their availability to wealthy individuals or countries, further widening the gap between those with access to cutting-edge healthcare and those without. Ensuring equitable access to the benefits of genetic engineering will be a major challenge for healthcare systems worldwide [8].

As genetic testing becomes more widespread, there is a growing risk of genetic discrimination. Employers, insurance companies, and even governments could potentially use an individual's genetic information to make decisions about employment, insurance coverage, or eligibility for certain services. Although laws like the Genetic Information Nondiscrimination Act (GINA) in the United States aim to prevent such abuses, concerns remain about the potential misuse of genetic data in the future [9].

Since genetic engineering is still a relatively new field, there is a limited understanding of its long-term effects. Changes made to the human genome may have unforeseen consequences that could emerge generations later. Additionally, the irreversible nature of some genetic modifications means that mistakes could have permanent, far-reaching implications.

*Correspondence to: Andrew Henslee, Department of Chemical and Biomolecular Engineering, Ohio State University, USA, E-mail: andrewhenslee@hotmail.com

Received: 01-Oct-2024, Manuscript No. AAAIB-24-148722; Editor assigned: 02-Oct-2024, PreQC No. AAAIB-24-148722 (PQ); Reviewed: 15-Oct-2024, QC No. AAAIB-24-148722; Revised: 22-Oct-2024, Manuscript No. AAAIB-24-148722 (R); Published: 28-Oct-2024, DOI: 10.35841/aaaib-8.5.228

This uncertainty underscores the need for thorough research and careful regulation as genetic engineering technologies continue to develop [10].

Conclusion

The impact of genetic engineering on human health is profound, offering unprecedented opportunities to treat, prevent, and even cure a range of diseases. From gene therapy and CRISPR to germline editing and personalized medicine, the potential benefits of this technology are extraordinary. However, alongside these promises come significant risks, including ethical dilemmas, unintended genetic consequences, and concerns about equity and accessibility.

References

1. Aarestrup F. M. Effect of Abolishment of the Use of Antimicrobial Agents for Growth Promotion on Occurrence of Antimicrobial Resistance in Fecal Enterococci from Food Animals in Denmark. *Anti-Micro Agents Chemo Ther.* 2001;45(7):2054–59.
2. Baqui A.H. Effect of Zinc Supplementation Started during Diarrhoea on Morbidity and Mortality in Bangladeshi Children: Community Randomised Trial. *Med J.* 2002;325(7372):1059.
3. Carey B., Cryan B. Antibiotic Misuse in the Community—A Contributor to Resistance. *Med J.* 2003;96(2):43–44. 46.
4. Duse A. G. Challenges Posed by Antimicrobial Resistance in Developing Countries. *Inf Dis Anti Res.* 1999;5(2):193–201.
5. Greenberg A. E. Hospital-Based Surveillance of Malaria-Related Paediatric Morbidity and Mortality in Kinshasa, Zaire. *World Hea Org.* 1989;67(2):189–96.
6. Fisher M.C., Koenig G. Biogeographic range expansion into South America by *Coccidioides immitis* mirrors New World patterns of human migration. *Proc. Natl. Acad. Sci. USA.* 2014;8(4):255-8.
7. Litvintseva A.P. Valley Fever: Finding new places for an old disease: *Coccidioides immitis* found in Washington State soil associated with recent human infection. *Clin. Infect. Dis.* 2009;206(10):20-5.
8. Benedict K.. Mycotic infections acquired outside areas of known endemicity. *Emerg. Infect. Dis.* 2017;23(2):1-7.
9. Gorris M.E.. *Coccidioidomycosis* dynamics in relation to climate in the southwestern United States. *Geo Health.* 2001;358(92):9.
10. Emmons C.W. Isolation of *Coccidioides* from soil and rodents. *Publ. Health Rep.* 2020;19:587(45):13-9.